Imatinib and Nilotinib Inhibit Hematopoietic Progenitor Cell Growth, but Do Not Prevent Adhesion, Migration and Engraftment of Human Cord Blood CD34(+) Cells

BACKGROUND: The availability of tyrosine kinase inhibitors (TKIs) has considerably changed the management of Philadelphia chromosome positive leukemia. The BCR-ABL inhibitor imatinib is also known to inhibit the tyrosine kinase of the stem cell factor receptor, c-Kit. Nilotinib is 30 times more pote...

Descripción completa

Detalles Bibliográficos
Autores principales: Belle, Ludovic, Bruck, France, Foguenne, Jacques, Gothot, André, Beguin, Yves, Baron, Frédéric, Briquet, Alexandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3527577/
https://www.ncbi.nlm.nih.gov/pubmed/23285088
http://dx.doi.org/10.1371/journal.pone.0052564

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3527577/
https://www.ncbi.nlm.nih.gov/pubmed/23285088
http://dx.doi.org/10.1371/journal.pone.0052564

Ejemplares similares